You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial
|
|---|---|
| Published in |
Multiple Sclerosis Journal, December 2013
|
| DOI | 10.1177/1352458513517590 |
| Pubmed ID | |
| Authors |
Anne Wickström, Charlotte Dahle, Magnus Vrethem, Anders Svenningsson |
| Abstract |
In a retrospective study, we have previously shown that work ability was improved after the initiation of natalizumab treatment in relapsing-remitting multiple sclerosis (RRMS). In another prospective trial (TYNERGY) the effect on MS-related fatigue was evaluated after 12 months of treatment with natalizumab. A comprehensive Capacity for Work Questionnaire (CWQ) was used to collect data regarding number of working hours and sickness absence. The predefined intention-to-treat analysis regarding work ability did not, however, show significant results. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 4 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 11% |
| Other | 6 | 9% |
| Researcher | 6 | 9% |
| Student > Master | 6 | 9% |
| Student > Ph. D. Student | 5 | 8% |
| Other | 11 | 17% |
| Unknown | 24 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 31% |
| Nursing and Health Professions | 5 | 8% |
| Psychology | 3 | 5% |
| Sports and Recreations | 3 | 5% |
| Economics, Econometrics and Finance | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 27 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2020.
All research outputs
#1,632,283
of 22,711,645 outputs
Outputs from Multiple Sclerosis Journal
#313
of 3,444 outputs
Outputs of similar age
#19,989
of 304,981 outputs
Outputs of similar age from Multiple Sclerosis Journal
#10
of 67 outputs
Altmetric has tracked 22,711,645 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,444 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,981 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.